TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 25005818

Group type: EXPERIMENTAL
Intervention: Neighborhood physical disorder
Number of subjects: 398

Group type: EXPERIMENTAL
Intervention: Neighborhood social environment
Number of subjects: 398
Study: 23474245

Group type: EXPERIMENTAL
Intervention: Intensified antihypertensive therapy
Number of subjects: 4078
Study: 21681065

Group type: EXPERIMENTAL
Intervention: Spinomed orthosis
Number of subjects: 0
Study: 18728576

Group type: EXPERIMENTAL
Intervention: Nicardipine (NC)
Number of subjects: 163

Group type: COMPARATOR
Intervention: Sodium Nitroprusside (SNP)
Number of subjects: 163
Study: 16944007

Group type: EXPERIMENTAL
Intervention: YHK
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 12629234

Group type: EXPERIMENTAL
Intervention: Bipolar deep brain stimulation at 90 micros, 130 Hz, adjusting the voltage up to 3 V
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Monopolar deep brain stimulation
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Bipolar deep brain stimulation at 120 micros, 185 Hz, 4 V
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Longest pulsewidth tested
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Frequency changes
Number of subjects: 11
Study: 10568896

Group type: EXPERIMENTAL
Intervention: Recruitment strategies used in the SMILE trial
Number of subjects: 0
Study: 9213716

Group type: EXPERIMENTAL
Intervention: Intravenous magnesium (17 g MgSO4 in 1000 ml isotonic saline)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Placebo (equal volumes of saline)
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Intravenous magnesium
Number of subjects: 61

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 61
Study: 1909083

Group type: EXPERIMENTAL
Intervention: Fluvoxamine (100-200 mg daily)
Number of subjects: 57

Group type: COMPARATOR
Intervention: Mianserin (40-80 mg daily)
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Fluvoxamine
Number of subjects: 57

Group type: COMPARATOR
Intervention: Mianserin
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Fluvoxamine and Mianserin
Number of subjects: 57
Study: 6343041

Group type: EXPERIMENTAL
Intervention: Human insulin (Novo)
Number of subjects: 47

Group type: COMPARATOR
Intervention: Purified pork insulin
Number of subjects: 47
Study: 31574899

Group type: EXPERIMENTAL
Intervention: Animal-Assisted Therapy (AAT) with the presence of a dog during a break (Condition C)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Normal working process with a break of choice (Condition B)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Normal working process without a break (Condition A)
Number of subjects: 20
Study: 30931588

Group type: EXPERIMENTAL
Intervention: Lactobacillus reuteri (2 probiotic tablets 2× per day for 21 days)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Scaling and root planing (SRP)
Number of subjects: 34
Study: 28379172

Group type: EXPERIMENTAL
Intervention: Exercise (EX) - 4 × 30 s 'flat-out' cycling on an ergometer
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Exercise (EX)
Number of subjects: 8

Group type: COMPARATOR
Intervention: REST
Number of subjects: 8
Study: 25542064

Group type: EXPERIMENTAL
Intervention: 125 mg famciclovir
Number of subjects: 167

Group type: COMPARATOR
Intervention: Placebo (125 mg)
Number of subjects: 167

Group type: EXPERIMENTAL
Intervention: 500 mg famciclovir
Number of subjects: 167

Group type: COMPARATOR
Intervention: Placebo (500 mg)
Number of subjects: 167
Study: 23592669

Group type: EXPERIMENTAL
Intervention: Cooperative exergame
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Competitive exergame
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Cooperative exergame and Competitive exergame
Number of subjects: 54

Group type: COMPARATOR
Intervention: Control
Number of subjects: 54
Study: 20489689

Group type: EXPERIMENTAL
Intervention: Glyceryl trinitrate (GTN) high-dose
Number of subjects: 38
Study: 19502570

Group type: EXPERIMENTAL
Intervention: Experimental mobile mandibular advancement splint (MAS) with LDPE connectors
Number of subjects: 30

Group type: COMPARATOR
Intervention: Conventional mobile MAS (Silensor)
Number of subjects: 30
Study: 16680253

Group type: EXPERIMENTAL
Intervention: Diclofenac (1 mg x kg(‐1) intramuscular) + remifentanil (0.1 microg x kg(‐1)min(‐1)) + ketamine (0.8 mg x kg(‐1) intravenously)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Remifentanil (0.1 microg x kg(‐1)min(‐1)) + ketamine (0.8 mg x kg(‐1) intravenously)
Number of subjects: 43
Study: 15571536

Group type: EXPERIMENTAL
Intervention: Unilateral resistance training of the operated side (3/wk x 12 weeks)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Unilateral neuromuscular electrical stimulation of the operated side (1 h/d x 12 weeks)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Standard home-based rehabilitation (1 h/d x 12 weeks)
Number of subjects: 36
Study: 11523155

Group type: EXPERIMENTAL
Intervention: Oral care (tooth brushing after each meal and daily oropharyngeal scrubbing with 1% povidone iodine)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Professional oral care (provided by dentists or dental hygienists once a week)
Number of subjects: 0
Study: 9020273

Group type: EXPERIMENTAL
Intervention: Deltibant (CP-0127) 0.3, 1.0, or 3.0 microg x kg(‐1) x min(‐1) continuous intravenous infusion
Number of subjects: 504

Group type: EXPERIMENTAL
Intervention: Deltibant (CP-0127)
Number of subjects: 504

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 504
Study: 7942581

Group type: EXPERIMENTAL
Intervention: Ascorbic acid (AA) 2 g/d
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study: 2833920

Group type: EXPERIMENTAL
Intervention: Nifedipine (20 mg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Lisinopril (20 mg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combination of nifedipine and lisinopril
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Nifedipine and Lisinopril
Number of subjects: 0
Study: 30341961

Group type: EXPERIMENTAL
Intervention: Short implants (6 mm; GS)
Number of subjects: 101

Group type: COMPARATOR
Intervention: Long implants (11-15 mm; GG)
Number of subjects: 101
Study: 26902851

Group type: EXPERIMENTAL
Intervention: galunisertib + lomustine
Number of subjects: 158

Group type: EXPERIMENTAL
Intervention: galunisertib
Number of subjects: 158

Group type: COMPARATOR
Intervention: placebo + lomustine
Number of subjects: 158

Group type: EXPERIMENTAL
Intervention: all treatment arms
Number of subjects: 158

Group type: EXPERIMENTAL
Intervention: galunisertib alone
Number of subjects: 158
Study: 24013981

Group type: EXPERIMENTAL
Intervention: Insulin glargine
Number of subjects: 2930

Group type: COMPARATOR
Intervention: Comparator treatments (oral antidiabetic drugs, dietary changes, or other insulins)
Number of subjects: 2930

Group type: COMPARATOR
Intervention: Comparator treatments
Number of subjects: 2930
Study: 24288511

Group type: EXPERIMENTAL
Intervention: Treatment (not specified in detail)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Normal controls
Number of subjects: 30
Study: 20484612

Group type: EXPERIMENTAL
Intervention: Single oral 40-mg dose of laropiprant (LRPT)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Healthy control participants (matched for important baseline characteristics)
Number of subjects: 16
Study: 18808281

Group type: EXPERIMENTAL
Intervention: Holistic Cognitive Interview (H‐CI)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Cognitive Interview (CI)
Number of subjects: 0
Study: 16864469

Group type: EXPERIMENTAL
Intervention: Medicaid managed care
Number of subjects: 255

Group type: COMPARATOR
Intervention: Comparison group (other publicly funded adolescents)
Number of subjects: 255
Study: 12649628

Group type: EXPERIMENTAL
Intervention: Fluoxetine (20 mg/day)
Number of subjects: 74

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 74
Study: 11732513

Group type: EXPERIMENTAL
Intervention: 0.2% ropivacaine
Number of subjects: 203

Group type: COMPARATOR
Intervention: 0.1% bupivacaine with fentanyl
Number of subjects: 203
Study: 8820475

Group type: EXPERIMENTAL
Intervention: Fish oil (4.5 g omega‐3 fatty acids/day)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study: 1427365

Group type: EXPERIMENTAL
Intervention: Endoscopic injection therapy
Number of subjects: 120

Group type: COMPARATOR
Intervention: Heater probe therapy
Number of subjects: 120
Study: 6994084

Group type: EXPERIMENTAL
Intervention: Cimetidine 400 mg at bedtime or twice daily for up to 12 months
Number of subjects: 696

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 696

Group type: EXPERIMENTAL
Intervention: Cimetidine
Number of subjects: 696
Study: 31313626

Group type: EXPERIMENTAL
Intervention: Forced exercise and RTP (FE+RTP)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Voluntary exercise and RTP (VE+RTP)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Time‐matched stroke‐related education and RTP (Edu+RTP)
Number of subjects: 40
Study: 27910260

Group type: EXPERIMENTAL
Intervention: Small-quantity lipid-based nutrient supplements (SQ-LNS)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not receiving SQ-LNS)
Number of subjects: 0
Study: 25827654

Group type: EXPERIMENTAL
Intervention: Lower body resistance training (3 times a week for 8 weeks)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Duration-matched stretch exercises (Control)
Number of subjects: 56
Study: 21189483

Group type: EXPERIMENTAL
Intervention: Routine opt-out provider-initiated HIV testing and counseling (PITC)
Number of subjects: 1221

Group type: COMPARATOR
Intervention: Standard non-PITC (voluntary or diagnostic testing)
Number of subjects: 1221

Group type: EXPERIMENTAL
Intervention: PITC
Number of subjects: 1221
Study: 19589767

Group type: EXPERIMENTAL
Intervention: Educational intervention on lifestyle modifications for GERD (10 minutes of education)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (no educational intervention)
Number of subjects: 30
Study: 17323134

Group type: EXPERIMENTAL
Intervention: Clopidogrel
Number of subjects: 136

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 136
Study: 16750703

Group type: EXPERIMENTAL
Intervention: Atorvastatin 80 mg
Number of subjects: 4162

Group type: COMPARATOR
Intervention: Pravastatin 40 mg
Number of subjects: 4162

Group type: EXPERIMENTAL
Intervention: Intensive statin therapy (including atorvastatin)
Number of subjects: 4162
Study: 14658972

Group type: EXPERIMENTAL
Intervention: Mirtazapine (15-45 mg/day)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Fluoxetine (20-40 mg/day)
Number of subjects: 19
Study: 9974197

Group type: EXPERIMENTAL
Intervention: Salmeterol 50 micrograms
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 8561100

Group type: EXPERIMENTAL
Intervention: High activity and intensity of response during infancy (measured at 8 months of age)
Number of subjects: 640

Group type: EXPERIMENTAL
Intervention: Risk factors for females
Number of subjects: 640
Study: 2106277

Group type: EXPERIMENTAL
Intervention: Sodium cromoglycate hypoosmolar solution (40 mOsmol/L)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Sodium cromoglycate isoosmolar solution (288 mOsmol/L)
Number of subjects: 14
Study: 7373088

Group type: EXPERIMENTAL
Intervention: Ribavirin (1,000 mg/day for five days)
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: Ribavirin
Number of subjects: 97

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 97
Study: 30795718

Group type: EXPERIMENTAL
Intervention: Fotonovela
Number of subjects: 303

Group type: COMPARATOR
Intervention: Traditional brochure
Number of subjects: 303

Group type: COMPARATOR
Intervention: No-message control group
Number of subjects: 303
Study: 30222631

Group type: EXPERIMENTAL
Intervention: Cholecalciferol (7.5mg, 300,000 IU; 15mL)
Number of subjects: 79

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 79
Study: 27633076

Group type: EXPERIMENTAL
Intervention: Neurodevelopmental treatment (NDT) + Vestibular training (VR)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Neurodevelopmental treatment (NDT)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Vestibular training (VR)
Number of subjects: 14
Study: 25171666

Group type: EXPERIMENTAL
Intervention: Electrical stimulation treatment in addition to physical therapy (5 days per week for 3 weeks)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Conventional physical therapy (hot pack, facial expression exercises, and massage)
Number of subjects: 60
Study: 23176373

Group type: EXPERIMENTAL
Intervention: Laser heat therapy (LHT)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Sham heat therapy (SHT)
Number of subjects: 38
Study: 21995469

Group type: EXPERIMENTAL
Intervention: Tropisetron (5 mg)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Metoclopramide (10 mg)
Number of subjects: 100
Study: 18331945

Group type: EXPERIMENTAL
Intervention: 40% chlorhexidine varnish (40%CHX)
Number of subjects: 60

Group type: COMPARATOR
Intervention: 1% chlorhexidine/1% thymol varnish (1%CHX)
Number of subjects: 60
Study: 17274493

Group type: EXPERIMENTAL
Intervention: Menatetrenone (vitamin K2)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combined treatment with bisphosphonates and menatetrenone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Menatetrenone
Number of subjects: 0

Group type: COMPARATOR
Intervention: Bisphosphonates
Number of subjects: 0
Study: 12812815

Group type: EXPERIMENTAL
Intervention: High-level intervention group (interactive group sessions and mailed modules)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Low-level intervention group (mailed modules only)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 0
Study: 10820872

Group type: EXPERIMENTAL
Intervention: Extracorporeal shockwave therapy (ESWT) with 3 sessions of low energy ESWT (2000 impulses, energy flux density 0.07-0.09 mJ/mm2)
Number of subjects: 272

Group type: COMPARATOR
Intervention: Sham-ESWT (placebo control)
Number of subjects: 272
Study: 9029412

Group type: EXPERIMENTAL
Intervention: Gly‐340‐Ser variant
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: 1083T variant
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Ser‐340 variant
Number of subjects: 42

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 42
Study: 1814447

Group type: EXPERIMENTAL
Intervention: Conservative local therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Surgical intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conservative local treatment
Number of subjects: 0
Study: 6881078

Group type: EXPERIMENTAL
Intervention: Zinc supplement
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control
Number of subjects: 40
Study: 31973208

Group type: EXPERIMENTAL
Intervention: Champ4life lifestyle intervention
Number of subjects: 94
Study: 31048072

Group type: EXPERIMENTAL
Intervention: Mathematically expressed criterion for likely cases of alternative classifications
Number of subjects: 0

Group type: COMPARATOR
Intervention: No computable criterion
Number of subjects: 0
Study: 28994676

Group type: EXPERIMENTAL
Intervention: IPPV
Number of subjects: 44

Group type: COMPARATOR
Intervention: NIPPV
Number of subjects: 44
Study: 27022637

Group type: EXPERIMENTAL
Intervention: Low-dose subperiosteal anaesthesia (0.9 ml of articaine with 0.5% epinephrine)
Number of subjects: 120

Group type: COMPARATOR
Intervention: High-dose infiltration anaesthesia (7.2 ml of articaine with 0.5% epinephrine)
Number of subjects: 120
Study: 24685937

Group type: EXPERIMENTAL
Intervention: Acceptance and mindfulness-based stress management workshop (n=66)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Waiting list control (n=54)
Number of subjects: 120
Study: 22644006

Group type: EXPERIMENTAL
Intervention: Transumbilical approach (group A)
Number of subjects: 82

Group type: COMPARATOR
Intervention: Infra-umbilical approach (group B)
Number of subjects: 82
Study: 19384124

Group type: EXPERIMENTAL
Intervention: Antenatal betamethasone (2x12 mg)
Number of subjects: 63

Group type: COMPARATOR
Intervention: Control group (no betamethasone)
Number of subjects: 63
Study: 17442091

Group type: EXPERIMENTAL
Intervention: Topical zinc oxide 20% ointment
Number of subjects: 44

Group type: COMPARATOR
Intervention: Salicylic acid 15% + lactic acid 15% ointment
Number of subjects: 44
Study: 14767239

Group type: EXPERIMENTAL
Intervention: Arm-crank exercise (40 rpm) in 35 degrees C, 50% RH for 3 x 10-min bouts
Number of subjects: 22

Group type: COMPARATOR
Intervention: Control group (healthy peers)
Number of subjects: 22
Study: 12536697

Group type: EXPERIMENTAL
Intervention: Zafirlukast 20 mg twice daily plus inhaled budelade (half quantity of GINA standard), long-acting aminophyllin 0.2 g twice daily, and inhaled salbutamol when necessary
Number of subjects: 0

Group type: COMPARATOR
Intervention: Inhaled budelade of GINA standard quantity, long-acting aminophyllin 0.2 g twice daily, and inhaled salbutamol when necessary
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Zafirlukast 20 mg twice daily added to standard treatment for stable asthma
Number of subjects: 0
Study: 9430083

Group type: EXPERIMENTAL
Intervention: Egg feeding (two eggs daily)
Number of subjects: 161

Group type: COMPARATOR
Intervention: Egg substitute (control group)
Number of subjects: 161
Study: 8306009

Group type: EXPERIMENTAL
Intervention: Aggressive intervention (early angiography and PTCA)
Number of subjects: 5882

Group type: COMPARATOR
Intervention: Conservative therapies
Number of subjects: 5882
Study: 3121268

Group type: EXPERIMENTAL
Intervention: Total parenteral nutrition
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Elemental diet
Number of subjects: 36

Group type: COMPARATOR
Intervention: Personalized food exclusion diets
Number of subjects: 36
Study: 30335720

Group type: EXPERIMENTAL
Intervention: Low-Carbohydrate Ketogenic Diet (LCKD) (≤50 g or ≤10% daily intake of carbohydrates)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Low-Carbohydrate Ketogenic Diet (LCKD)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Usual Diet (UD) (>250 g daily intake of carbohydrates)
Number of subjects: 14
Study: 27756314

Group type: EXPERIMENTAL
Intervention: Communication for behavioural impact (COMBI) strategy
Number of subjects: 761
Study: 24401173

Group type: EXPERIMENTAL
Intervention: Advance telephone call ahead of reminder questionnaire (n=390)
Number of subjects: 753

Group type: COMPARATOR
Intervention: Usual reminder schedule only (n=363)
Number of subjects: 753
Study: 23442318

Group type: EXPERIMENTAL
Intervention: AOD use among Coloured women
Number of subjects: 720

Group type: EXPERIMENTAL
Intervention: AOD use among Black African women
Number of subjects: 720

Group type: EXPERIMENTAL
Intervention: AOD impairment during last sexual encounter
Number of subjects: 720

Group type: EXPERIMENTAL
Intervention: Partner AOD impairment
Number of subjects: 720
Study: 20097908

Group type: EXPERIMENTAL
Intervention: Caregivers of children with T1D
Number of subjects: 195

Group type: EXPERIMENTAL
Intervention: Caregivers of children with CF
Number of subjects: 195
Study: 18411010

Group type: EXPERIMENTAL
Intervention: Transdermal buprenorphine 70 microg/h (BUP TDS)
Number of subjects: 289

Group type: COMPARATOR
Intervention: Placebo patch
Number of subjects: 289
Study: 15927144

Group type: EXPERIMENTAL
Intervention: Behaviour therapy (BT) consisting of self-control procedures offered in six sessions
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Behaviour therapy (BT)
Number of subjects: 28
Study: 12645707

Group type: EXPERIMENTAL
Intervention: Perioperative prophylactic hemodialysis (dialysis group, 21 patients)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Control group (23 patients, hemodialysis only if postoperative acute renal failure diagnosed)
Number of subjects: 44
Study: 10754364

Group type: EXPERIMENTAL
Intervention: Amino acid infusion
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control (no amino acid infusion)
Number of subjects: 20
Study: 8595829

Group type: EXPERIMENTAL
Intervention: Silver amalgam restorations placed in posterior teeth
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (no amalgam restorations)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Experimental group (silver amalgam restorations)
Number of subjects: 60
Study: 1981000

Group type: EXPERIMENTAL
Intervention: Antacid (80 ml of suspension; Maalox 70) administered on the evening before dosing and again 2 h before and 2 h after breakfast
Number of subjects: 18
Study: 7012191

Group type: EXPERIMENTAL
Intervention: Chlorpheniramine maleate, 4 times daily for one week
Number of subjects: 106

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 106
Study: 31467892

Group type: EXPERIMENTAL
Intervention: rTMS over the right posterior superior temporal gyrus (pSTG)
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: rTMS over the right pars triangularis of the posterior inferior frontal gyrus (pIFG)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 54
Study: 29385005

Group type: EXPERIMENTAL
Intervention: 6 hours before + immediately before (photobiomodulation therapy [PBMT] applied both 6 hours before and immediately before the test)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Immediately before (placebo applied 6 hours before and PBMT applied immediately before the test)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16

Group type: COMPARATOR
Intervention: Immediately before
Number of subjects: 16
Study: 27745820

Group type: EXPERIMENTAL
Intervention: Pembrolizumab plus carboplatin and pemetrexed
Number of subjects: 123

Group type: COMPARATOR
Intervention: Chemotherapy alone (carboplatin and pemetrexed)
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: Pembrolizumab plus chemotherapy
Number of subjects: 123

Group type: COMPARATOR
Intervention: Chemotherapy alone
Number of subjects: 123
Study: 25005597

Group type: EXPERIMENTAL
Intervention: Long hospital discharge letter provided immediately
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Short hospital discharge letter provided immediately
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Long hospital discharge letter provided 1 week later
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Short hospital discharge letter provided 1 week later
Number of subjects: 59
Study: 22569690

Group type: EXPERIMENTAL
Intervention: Flexible cystoscopy (FC)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Rigid cystoscopy (RC)
Number of subjects: 100
Study: 20130232

Group type: EXPERIMENTAL
Intervention: CCR5Delta32 deletion
Number of subjects: 5748

Group type: EXPERIMENTAL
Intervention: Single-nucleotide polymorphisms (rs1154428, rs6808835, rs6791599) in CCRL2
Number of subjects: 5748

Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 5748